Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Cash & Current Investments (2018 - 2025)

Historic Cash & Current Investments for BioNexus Gene Lab (BGLC) over the last 8 years, with Q3 2025 value amounting to $3.1 million.

  • BioNexus Gene Lab's Cash & Current Investments rose 1625.58% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year increase of 1625.58%. This contributed to the annual value of $5.7 million for FY2024, which is 2574.76% up from last year.
  • According to the latest figures from Q3 2025, BioNexus Gene Lab's Cash & Current Investments is $3.1 million, which was up 1625.58% from $3.8 million recorded in Q2 2025.
  • BioNexus Gene Lab's 5-year Cash & Current Investments high stood at $6.1 million for Q3 2023, and its period low was $1.1 million during Q1 2025.
  • In the last 5 years, BioNexus Gene Lab's Cash & Current Investments had a median value of $2.1 million in 2021 and averaged $2.9 million.
  • As far as peak fluctuations go, BioNexus Gene Lab's Cash & Current Investments skyrocketed by 32036.61% in 2023, and later tumbled by 8129.0% in 2025.
  • Quarter analysis of 5 years shows BioNexus Gene Lab's Cash & Current Investments stood at $2.1 million in 2021, then dropped by 0.24% to $2.1 million in 2022, then skyrocketed by 113.21% to $4.5 million in 2023, then increased by 25.75% to $5.7 million in 2024, then plummeted by 45.46% to $3.1 million in 2025.
  • Its Cash & Current Investments was $3.1 million in Q3 2025, compared to $3.8 million in Q2 2025 and $1.1 million in Q1 2025.